Eli Lilly plans to introduce its weight-loss pill, orforglipron, in India, offering a non-injectable alternative that may appeal to patients wary of injections. Orforglipron belongs to the GLP-1 drug class, which curbs appetite and mirrors the mechanism of Lilly’s successful injectables Mounjaro and Zepbound. Though not yet approved anywhere globally,...